Stop Sabotaging Your Trials: 3 Site Selection Mistakes to Fix Now

The High Cost of Poor Site Selection: Why Your Trial Is Already at Risk

Every clinical trial begins with a critical decision: which sites will conduct the study. Yet many sponsors and CROs treat site selection as an administrative formality rather than a strategic determinant of trial success. The consequences are severe—delayed timelines, blown budgets, and failed enrollment. Industry analyses consistently show that 80% of trials fail to meet their original enrollment timelines, and site selection factors are implicated in a significant portion of these failures. This article addresses the root cause: three common site selection mistakes that sabotage trials, and how to fix them before it's too late.

When we rush site selection, we often default to familiar investigators or sites with impressive CVs, ignoring hard questions about patient access, infrastructure, and commitment. A single underperforming site can derail the entire trial—creating bottlenecks in data collection, requiring protocol amendments, and draining resources that could have been deployed elsewhere. The problem is not just about picking the wrong sites; it's about not having a systematic process to identify the right ones.

We'll explore each mistake in depth, then provide a repeatable framework to avoid them. If you're a clinical operations manager, a project lead at a CRO, or a sponsor executive, the insights here will help you shift from reactive site selection to proactive, data-driven decision-making. The goal is not just to avoid mistakes, but to build a site selection strategy that accelerates timelines and improves data quality.

The Real Cost of One Bad Site

Consider a typical Phase 3 trial aiming to enroll 300 patients across 30 sites. If even 3 sites (10%) consistently underperform—enrolling slowly, producing low-quality data, or dropping out—the ripple effects can delay the entire study by months, increasing costs by hundreds of thousands of dollars. Beyond financial loss, a delayed trial can mean delayed access to therapy for patients who need it. This is why site selection deserves the same rigor as protocol design.

Many organizations still rely on spreadsheets and gut feelings. The result is a high rate of site-initiated terminations (around 20% in some therapeutic areas), which not only wastes setup costs but also erodes trust with patients and investigators. By understanding the three mistakes we're about to discuss, you can dramatically reduce these risks and set your trial up for success from the start.

Mistake #1: Overlooking True Investigator Experience and Commitment

The first mistake is equating an impressive publication record or a prestigious institution with clinical trial execution capability. While a renowned PI brings credibility, they may lack the bandwidth—or the team—to handle the operational demands of your protocol. We often see sites selected because the investigator is a thought leader in the disease area, yet that same investigator may be juggling multiple competing trials, have a high patient screen-failure rate, or lack a dedicated research coordinator. The result: slow enrollment, data queries, and eventual site dropout.

True investigator experience is not just about having done trials before—it's about having done similar trials, with similar patient populations, and with a track record of meeting enrollment targets on time. A PI who successfully enrolled a rare disease study with a narrow inclusion window is likely a better fit than a high-volume oncology PI who has never worked with your specific biomarker criteria. Beyond the PI, evaluate the entire site team. Who will actually consent patients, manage data entry, and handle regulatory submissions? Turnover among site staff is a hidden saboteur; if the coordinator who worked on your feasibility assessment leaves before enrollment starts, you lose institutional knowledge and momentum.

How to Assess Real Commitment

Start with a structured feasibility questionnaire that goes beyond yes/no questions. Ask for specific metrics: number of patients seen in the clinic per month that match your inclusion/exclusion criteria, historical screen-failure rates for similar protocols, and the number of ongoing trials at the site. Request a site visit (virtual or in-person) to meet the full research team, not just the PI. Observe their workflow: do they have a dedicated research space? Is there a system for tracking patient referrals? These details reveal true capacity.

Another powerful tactic is to check references—not just the ones the site provides. Contact other sponsors or CROs who have worked with the site in the past year. Ask about responsiveness, data quality, and whether the site met its enrollment timelines. This due diligence may take an extra week, but it prevents months of wasted effort.

Finally, verify that the site's commitment aligns with your timeline. Some sites agree to participate but cannot start enrollment for months due to backlog. A site that is enthusiastic but delayed can be more damaging than a site that declines outright. Incorporate a site readiness assessment into your feasibility process, and prioritize sites that can activate within your required window.

Mistake #2: Ignoring the Realities of Patient Population and Access

The second mistake is assuming that a site with a large patient database can recruit participants for your specific protocol. Patient databases often contain outdated information, and many patients listed are not actively seeking trial participation. Moreover, inclusion/exclusion criteria can drastically reduce the pool. A site that claims 500 patients with your condition may only have 50 who meet all criteria—and only 20 of those are willing to enroll in a trial. Without validating these numbers, you risk overestimating enrollment capacity.

Patient access also involves geographic and logistical factors. If your protocol requires frequent visits—such as weekly infusions—the site's location relative to patient populations becomes critical. A site in a rural area with limited public transportation may struggle to retain patients, even if the investigator is excellent. Similarly, if the trial involves a novel therapy that requires specialized monitoring, the site must have the necessary equipment and trained staff. Overlooking these operational realities leads to slow enrollment and high dropout rates.

Practical Steps to Match Site to Patient Population

Start by mapping the patient journey for your indication. Where do patients typically seek care? Which clinics or hospitals are most likely to see undiagnosed or treatment-resistant patients? Use claims data, electronic health records (EHRs), or published epidemiology to identify high-density areas. Then, shortlist sites in those regions—not just based on investigator reputation.

Next, conduct a granular feasibility assessment for each candidate site. Ask the site to run a query on their EHR system to count active patients who meet your key inclusion criteria. Ask for the number of patients seen in the last 12 months, not the total database. Also, inquire about competitor trials: if two other studies are enrolling the same patient population, your trial will face competition for the same limited pool. A site that is already participating in a similar trial may not have capacity to recruit for yours.

Finally, consider patient burden. If your protocol includes multiple biopsies or long clinic stays, assess whether the site provides support services like transportation assistance, flexible hours, or telemedicine visits where permitted. Sites that invest in patient retention—through coordinator outreach, reminder systems, and patient education—consistently achieve higher retention rates. Including these factors in your site selection criteria can dramatically improve enrollment and data completeness.

Mistake #3: Underestimating Site Infrastructure and Capacity

The third mistake is failing to evaluate the operational infrastructure that supports a successful trial. A site may have a brilliant PI and an eager patient population, but if their research department is understaffed, their data management system is outdated, or their regulatory team is overburdened, the trial will suffer. We've seen sites that lack a dedicated freezer for samples, have no backup plan for equipment failures, or rely on a single person to handle all regulatory submissions. When that person is on leave, the site grinds to a halt.

Capacity is not just about physical space; it's about the site's ability to manage the volume of work your trial requires. If the site is running 15 other studies simultaneously, your trial will inevitably compete for attention. Even with the best intentions, coordinators can only manage a finite number of patient visits, data queries, and monitoring visits. A site that takes on too many trials often compromises quality across all of them.

Building a Capacity Checklist

Create a standard capacity assessment for every potential site. Include items such as: number of full-time research coordinators, number of principal investigators (and their current trial load), availability of dedicated research space, existence of a clinical research unit, and access to ancillary services (pharmacy, lab, radiology). Also evaluate technology: does the site have a reliable EDC system? Can they handle remote source data verification? Are they comfortable with your ePRO or eCOA platform?

Another critical element is regulatory and ethics submission readiness. Sites with experience in your therapeutic area often have faster IRB turnaround times. Ask for their average time from contract execution to first patient enrolled. This metric reveals how efficiently the site can operationalize a trial. Sites that have a streamlined process—such as pre-approved templates or an internal IRB—can activate weeks faster, which translates to earlier enrollment.

Finally, don't overlook financial infrastructure. Some sites struggle with payment cycles or lack the cash flow to support early-stage costs. If a site requires upfront payment for equipment or staffing, and your company's payment terms are net-60, this can cause friction. Discuss these details during the feasibility phase, and ensure both parties are aligned on financial expectations. A site that is financially strained may cut corners or drop out mid-trial.

A Repeatable Framework for Site Selection: From Feasibility to Activation

Now that we've identified the three mistakes, let's build a systematic process to avoid them. A robust site selection framework moves through four phases: pre-screen, feasibility survey, in-depth assessment, and final selection. Each phase answers a specific question: Can this site technically do the trial? Does it have the patient population? Does it have capacity to start on time? And is there a mutual commitment to succeed?

Phase 1: Pre-Screen

Start with a broad list of potential sites based on therapeutic expertise, geographic coverage, and past performance (if known). Use a simple scoring tool (e.g., 1-5 scale) for each criterion: investigator experience, patient access, site infrastructure, and prior trial performance. Eliminate sites that score below a threshold (e.g., 2.5 average). This phase should be quick—aim to reduce your list by 50% in a few days.

Phase 2: Feasibility Survey

Send a structured questionnaire to the remaining sites. Include questions about: number of eligible patients seen in the last 12 months, screen failure rates for similar protocols, current trial load, staff turnover, and average time from contract to enrollment. Ask for evidence: EHR query results, staff resumes, or previous monitoring visit reports. Review responses carefully and rank sites. Follow up with a phone call to clarify any red flags.

Phase 3: In-Depth Assessment

For top-ranked sites, conduct a site visit (virtual or in-person). Meet the full team, tour the facilities, and review standard operating procedures. Discuss protocol specifics: inclusion/exclusion criteria, visit schedule, and data collection requirements. Assess the site's willingness to adapt—for example, can they schedule additional visits if needed? Also, discuss contingency plans for staff turnover, equipment failure, or patient no-shows. This phase separates promising sites from truly prepared ones.

Phase 4: Final Selection and Activation

Based on the in-depth assessment, select sites that meet your criteria. Before finalizing, check references from other sponsors or CROs. Then negotiate the contract with clear performance milestones (e.g., first patient enrolled within 8 weeks of activation). Include provisions for site support—such as dedicated CRA oversight or enrollment support tools—to set the site up for success. Activation should be a collaborative process, not a handover.

By following this framework, you replace guesswork with data, and you build a network of sites that are not just able, but also motivated to deliver. The investment in upfront assessment pays dividends in enrollment speed, data quality, and overall trial success.

Tools, Technology, and Economics of Better Site Selection

Implementing this framework is easier with the right tools and an understanding of the economic benefits. Many organizations now use site selection software that integrates with EHR data, claims databases, and feasibility platforms. These tools can automate patient count estimates, site performance benchmarking, and competitive trial landscape analysis. While the upfront cost may be significant (annual licenses range from $10,000 to $50,000+ for enterprise solutions), the return on investment is substantial when you consider the cost of a delayed trial.

Comparing Site Selection Approaches

Beyond software, consider the economics of site selection. Each site that fails to enroll costs an average of $15,000-$30,000 in startup costs (site qualification, IRB submission, contract negotiation, training). If you initiate 10 sites that later underperform, you've wasted $150,000-$300,000—money that could have been used to support high-performing sites. By investing an extra $5,000 per site in thorough feasibility, you can reduce the failure rate and save overall costs.

Another economic factor is enrollment duration. Every month of delay can cost tens of thousands of dollars in project management overhead, CRA travel, and monitoring costs. For a Phase 3 trial, a 3-month delay can exceed $1 million in added expenses and lost market opportunity. Better site selection directly reduces these risks by ensuring you activate sites that are ready to enroll quickly.

Technology also enables centralized performance tracking. Once sites are selected, you can use dashboards to monitor enrollment rates, query volumes, and screen failure rates in real time. This allows you to intervene early if a site is underperforming—perhaps by providing additional training or adjusting recruitment strategies. Tools like Medidata Rave, Veeva Vault, and specialized enrollment management platforms offer these capabilities. While the initial learning curve is real, the long-term benefits in data quality and operational efficiency are proven.

Pitfalls and Mitigations: Staying on Track After Site Selection

Even with a rigorous selection process, challenges emerge. Common pitfalls include overestimating site readiness, failing to maintain communication, and not having contingency plans. Recognizing these risks early allows you to mitigate them before they escalate.

Pitfall 1: Overestimating Site Readiness Post-Selection

Sometimes a site passes feasibility but struggles during activation—perhaps because the coordinator who completed the survey leaves, or the PI becomes unavailable due to a competing trial. Mitigate this by building a post-selection readiness checklist. After contract signing, schedule a kickoff call to confirm the team is still intact and the timeline is realistic. If key staff have changed, consider re-assessing the site's capacity. It's better to delay activation by a month than to start with a compromised team.

Pitfall 2: Poor Communication and Misaligned Expectations

Many sites report that sponsors overload them with queries or change procedures without notice. To avoid this, establish clear communication channels from the start. Designate a primary contact at the CRO and the site. Provide a site manual that outlines escalation paths, data entry timelines, and query response expectations. Regularly scheduled check-ins (weekly during enrollment, bi-weekly during maintenance) prevent small issues from becoming major roadblocks.

Pitfall 3: Lack of Contingency Planning

Even the best sites can face unforeseen events—natural disasters, institutional policy changes, or key staff departures. Include a contingency clause in your contract that allows for site replacement if enrollment falls below a certain threshold (e.g., less than 50% of target by a specified date). Also, maintain a list of backup sites that were strong candidates during selection but not chosen. If a site fails, you can activate a backup without restarting the entire selection process.

Another effective mitigation is to over-enroll sites initially—activate 10-15% more sites than your target. This buffer accounts for underperformers without delaying the overall timeline. The extra cost of activating one or two additional sites is far less than the cost of a trial extension.

Finally, consider using risk-based monitoring to focus resources on sites that may be struggling. Instead of monitoring all sites equally, allocate more CRAs to sites with slower enrollment or higher query rates. This targeted approach improves data quality and can identify problems early, allowing for timely intervention.

Frequently Asked Questions and Decision Checklist

To help you apply these concepts immediately, we've compiled common questions and a practical checklist for your next site selection process.

FAQ

Q: Should we always select the top academic medical centers? Not necessarily. While they bring prestige, they often have complex IRB processes, high overhead, and many competing trials. Community-based sites can sometimes enroll faster and at lower cost. Evaluate each site on its merits for your specific protocol.

Q: How many sites should we activate for a Phase 2 trial? There's no one-size-fits-all answer, but a common approach is to estimate your needed enrollment rate and then add a 15-20% buffer. Use historical data or feasibility surveys to determine average enrollment per site per month. Then calculate the number of sites required to meet your target timeline.

Q: What if a site passes feasibility but then fails to enroll? First, investigate the cause—is it the site's performance, or are there protocol-specific barriers? Sometimes the inclusion criteria are too restrictive, or the patient population is more complex than anticipated. If the issue is at the site, consider providing additional support (e.g., an enrollment specialist) or, if necessary, replacing the site early to avoid prolonged delays.

Q: How do we handle sites in different countries? International site selection adds complexity—consider regulatory timelines, language barriers, cultural differences in patient consent, and logistics for drug shipment. The same principles apply, but you may need to partner with a local CRO or feasibility expert to assess each region accurately.

Decision Checklist for Site Selection

• Investigator Experience: Has the PI done a similar trial in the last 2 years? What is their screen failure rate? Are they committed to your timeline?
• Patient Access: How many active patients meet your inclusion criteria? Is the site located in an area with good patient access? Are there competing trials for the same population?
• Site Infrastructure: Does the site have dedicated research staff, adequate space, and reliable equipment? What is their average IRB turnaround time?
• Capacity: How many other trials are ongoing? What is the staff-to-patient ratio? Is there a backup plan for staff turnover?
• Financial Health: Can the site manage the payment schedule? Are there any financial constraints that might affect their performance?

Use this checklist as a starting point and adapt it to your specific therapeutic area and protocol complexity. The goal is to make site selection a data-driven, repeatable process—not a gamble.

From Mistakes to Mastery: Your Next Steps

Site selection is not a one-time event but a continuous improvement process. The three mistakes we've covered—overlooking investigator commitment, ignoring patient realities, and underestimating infrastructure—are common but entirely avoidable. By adopting a structured framework, leveraging the right tools, and maintaining open communication with sites, you can significantly improve your trial's chances of success.

Start with your current trial. Review your site selection decisions using the checklist above. Identify any sites that may have been chosen hastily or without sufficient data. For future trials, commit to a feasibility process that includes at least two of the four phases we described. Even small improvements—such as adding a site visit or requesting EHR data—can prevent major setbacks.

Remember, the goal is not to eliminate all risk; some uncertainty is inherent in clinical research. But by making smarter site choices, you reduce the most common sources of delay and cost overrun. Your patients, your team, and your organization will benefit from trials that enroll on time and produce high-quality data.

We encourage you to share this guide with your clinical operations team and discuss how you can implement these practices. Better site selection leads to better trials, and better trials lead to better treatments for patients who are waiting.